United Therapeutics (UTHR) Other Operating Expenses (2009 - 2026)

United Therapeutics has reported Other Operating Expenses for 18 years, with the latest figure at $133.4 million in Q1 2026.

• Quarterly Other Operating Expenses rose 44.22% year-over-year to $133.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $425.3 million (up 29.15% YoY) and the FY2025 annual result came in at $384.4 million, up 24.12% from the prior year.
• Other Operating Expenses improved to $133.4 million in Q1 2026 per UTHR's latest filing, from $103.4 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $133.4 million in Q1 2026 and troughed at $25.9 million in Q1 2022.
• A 5-year average of $72.7 million and a median of $72.9 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses sank 81.53% in 2022, then surged 115.82% in 2023.
• Over 5 years, Other Operating Expenses stood at $58.8 million in 2022, then advanced by 20.75% to $71.0 million in 2023, then grew by 6.9% to $75.9 million in 2024, then jumped by 36.23% to $103.4 million in 2025, then rose by 29.01% to $133.4 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $133.4 million, $103.4 million, and $100.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.